Effects of stromal cell-derived factor 1_ delivered at different phases of transient focal ischemia in rats-

Authors
J. Yoo, J.-J. Seo, J.-H. Eom, D.-Y. Hwang.


Lab
CHA University, College of Natural Science, Department of Biomedical Science, Seoul, Korea.

Journal
Neuroscience

Abstract
Endogenous stromal cell-derived factor 1_ (SDF1_) has been implicated in postischemic tissue repair, suggesting SDF1_ as a potential therapeutic molecule to treat stroke patients. In spite of its potential, no data are available regarding the short- and long-term effects of SDF1_ when it is delivered at different phases of stroke. In our study, adenovirus expressing SDF1_ gene (AV-SDF1_) was introduced into the boundary of the infarcted area either 3 days before or 1 week after ischemia, and behavioral performance was measured over 5 weeks. Immediate behavioral and structural amelioration was evident when AV-SDF1_ was injected 3 days before ischemia, which might be the result of SDF1_-mediated neuroprotection as supported by the TUNEL staining and Western blot analysis of active caspase-3. In addition, increase in neurogenesis, neuroblast migration, and neural differentiation was also apparent in the AV-SDF1_-injected brain, which contributed to further amelioration at later time points (delayed response). On the contrary, when AV-SDF1_ was introduced 1 week post-ischemia (in the subacute phase), significant behavioral recovery became apparent beginning 5 weeks after viral delivery. Taken together, the therapeutic efficacy of SDF1_ varied considerably depending on when SDF1_ overexpression was initiated; initiating SDF1_ overexpression before ischemia exerted both immediate and delayed beneficial effects, whereas initiating overexpression in the subacute phase exerted only a delayed response.

BIOSEB Instruments Used:
Aron Test or Four Plates Test (LE830),Rotarod (BX-ROD)

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.